Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage TechBio company that regularly issues news and updates about its platform, pipeline and partnerships. As a biotechnology company focused on decoding biology to radically improve lives, Recursion generates announcements that span clinical trial readouts, business development milestones and technology advances related to its Recursion OS.
News for RXRX often highlights progress in clinical programs, such as the TUPELO Phase 1b/2 trial of REC-4881 in familial adenomatous polyposis (FAP), the ELUCIDATE Phase 1/2 trial of REC-617 in advanced solid tumors and ovarian cancer, and the DAHLIA Phase 1/2 study of REC-1245 in solid tumors. Company communications describe efficacy, safety, and design details for these studies, as well as plans for future data readouts and regulatory interactions.
Investors also see frequent updates on partnerships and collaborations. Recursion reports milestones from its long-term collaboration with Genentech and F. Hoffmann-La Roche Ltd, including acceptance of whole-genome phenotypic maps such as a microglia map, and from its multi-target collaboration with Sanofi in oncology and immunology. These items often include information about milestone payments and the scope of ongoing discovery work.
Additional RXRX news covers financial results and capital markets activity, such as quarterly earnings releases, cash runway commentary, and disclosures related to registration statements and share issuances connected to collaborations or acquisitions. The company also announces participation in healthcare and investor conferences, webinars on clinical data, and leadership changes, including CEO transition plans.
By following the RXRX news feed, readers can track how Recursion’s Recursion OS platform is being applied across its internal pipeline and partnered programs, as well as how business decisions, collaborations and governance developments may shape the company’s trajectory in the TechBio and biotechnology sectors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Recursion Pharmaceuticals (RXRX)?
What is the market cap of Recursion Pharmaceuticals (RXRX)?
